Table 6.

Univariate analysis of prognostic factors for survival after BT

FactorNo.Median survival (95% CI)P
Patient age, y    
 50 or younger 49 8.8  (7-10) .04  
 Older than 50 25 5.5  (4-7)  
WBC count at BT, × 109/L    
 No higher than 60 43 8.7  (5-12) .04  
 Higher than 60 19 5.6  (3-8)  
PB blasts at BT, %    
 No more than 50 35 8.2  (6-10) .025  
 More than 50 15 3.6  (0-7)  
Cytogenetic evolution    
 No 24 11.8  (9-15) .012  
 Yes 50 6.3  (5-7)  
Response to first/second therapy    
 CP 34 13  (10-17) .00001  
 No CP 40 5.7  (5-7)  
Pre-BT treatment    
 No more than 2 agents 37 8.7  (6-11) .05  
 More than 2 agents 35 6.8  (5-8)  
SCT    
 Yes 37 11  (8-14) .039 
 No 37 6.8  (5-8)  
Type of SCT    
 Allo 23 11.6  (10.7-12.5) .024 
 Auto 14 5.8  (3.5-8)  
FactorNo.Median survival (95% CI)P
Patient age, y    
 50 or younger 49 8.8  (7-10) .04  
 Older than 50 25 5.5  (4-7)  
WBC count at BT, × 109/L    
 No higher than 60 43 8.7  (5-12) .04  
 Higher than 60 19 5.6  (3-8)  
PB blasts at BT, %    
 No more than 50 35 8.2  (6-10) .025  
 More than 50 15 3.6  (0-7)  
Cytogenetic evolution    
 No 24 11.8  (9-15) .012  
 Yes 50 6.3  (5-7)  
Response to first/second therapy    
 CP 34 13  (10-17) .00001  
 No CP 40 5.7  (5-7)  
Pre-BT treatment    
 No more than 2 agents 37 8.7  (6-11) .05  
 More than 2 agents 35 6.8  (5-8)  
SCT    
 Yes 37 11  (8-14) .039 
 No 37 6.8  (5-8)  
Type of SCT    
 Allo 23 11.6  (10.7-12.5) .024 
 Auto 14 5.8  (3.5-8)  
Close Modal

or Create an Account

Close Modal
Close Modal